Author: ntuck

Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer

AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 3 STUDY OF PF-07248144 PLUS FULVESTRANT COMPARED TO INVESTIGATOR’S CHOICE OF THERAPY IN ADULT PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK4/6 INHIBITOR-BASED THERAPY

IZABRIGHT-Breast01: A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triplenegative Breast Cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for AntiPD1/PD-L1 Treatment

A phase IIIb study to characterize the efficacy and safety of Adjuvant ribociclib  plus endocrine therapy in a close-to-clinical practice patient population with HR+ HER2− early breast cancer (Adjuvant WIDER)

ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade

VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study of
Fulvestrant and CDK4/6 Inhibitors With or Without
Gedatolisib as First-Line Treatment in Patients With
HR-Positive and HER2-Negative Advanced Breast Cancer.